Physiological perspectives of therapy in bronchial hyperreactivity

Canadian Journal of Anaesthesia

Volumn 43, Issue 7, 1996, Pages 700-713

  Pinto Pereira, Lexley M ^a   Orrett, Fitzroy A ^a   Balbirsingh, Merle ^a  

^a NONE

Author keywords

AIRWAY: reversible obstruction; ANAESTHESIA: emergency; LUNG: bronchial hyperreactivity; PHARMACOLOGY: 2 agonists, theophylline, glucocorticoids

Indexed keywords

BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BITOLTEROL; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CROMAKALIM; FENOTEROL; FLUNISOLIDE; FORMOTEROL; GLUCOCORTICOID; GLYCOPYRRONIUM BROMIDE; HYDROCORTISONE; IPRATROPIUM BROMIDE; ISOETARINE; ISOPRENALINE; ORCIPRENALINE; SALBUTAMOL; SALMETEROL; STEROID; TERBUTALINE; THEOPHYLLINE DERIVATIVE;

AIRWAY DYNAMICS; BRONCHOSPASM; BRONCHUS HYPERREACTIVITY; FORCED EXPIRATORY VOLUME; HEART PALPITATION; HISTOPATHOLOGY; HUMAN; INFORMATION PROCESSING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TACHYCARDIA; TREMOR;

EID: 9544237123     PISSN: 0832610X     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03017956     Document Type: Review

References (104)

1. Newhouse MT, Dolovich MB. Control of asthma by aerosols. N Engl J Med 1986; 315: 870-4.
2. Chung KF. Inflammatory mechanisms in asthma. In: Barnes PJ (Ed.). Respiratory Medicine: Recent Advances. Oxford: Butterworth-Heinemann Ltd, 1993: 32-56.
3. Miller RD. Skeletal muscle relaxants. In: Katzung BG, (Ed.). Basic and Clinical Pharmacology, 6th. ed. Connecticut: Appleton and Lange, 1995: 404-18.
4. Fung D, Hanowell L, Smith NT. Anaesthetic considerations in asthmatic patients. In: Gershwin ME, Halpern GM (Eds.). Bronchial Asthma, Principles of Diagnosis and Treatment, 3rd ed. New Jersey: Humana Press, 1994: 639-60.
5. Kingston HG, Hirshman CA. Perioperative management of the patient with asthma. Anesth Analg 1984; 63: 844-55.
6. Allen SJ. Management of the patient with reactive airway disease. In: Stanley TH, Sperry RJ (Eds.). Anaesthesia and the Lung. The Netherlands: Kluwer Academic Publishers, 1992: 141-55.
7. McFadden. ER Jr, Hejel R. Asthma. Lancet 1995; 345: 1215-20.
8. Knight DA, Phillips MJ, Stewart GA, Thompson PJ. The interaction of acetylcholine and histamine on human bronchial smooth muscle contraction. Eur Respir J 1991; 4: 985-91.
9. Bolton TB. Mechanisms of action of transmitters and other substances on smooth muscle. Physiol Rev 1979; 59: 606-718.
10. Chideckel EW, Frost JL, Mike P, Fedan JS. The effect of ouabain on tension in isolated respiratory tract smooth muscle of humans and other species. Br J Pharmacol 1987; 92: 609-14.
11. Torphy TJ. Action of mediators on airway smooth muscle: functional antagonism as a mechanism for bronchodilator drugs. In: O'Donnell SR, Persson CGA (Eds.). Directions for New Anti-asthma Drugs, Agents and Actions Supplements, Vol 23. Basel: Birkhauser Verlag, 1987: 37-53.
12. Rodger IW. Calcium ion mechanisms in airway smooth muscle: potential targets for novel symptomatic drugs for asthma. In: O'Donnell SR, Persson CGA (Eds.). Directions for New Anti-asthma Drugs, Agents and Actions Supplements, Vol 23. Basel: Birkhauser Verlag, 1987: 69-87.
13. Rodger IW. Drugs affecting calcium ions in airway smooth muscle. In: Barnes PJ (Ed.). New Drugs for Asthma. London: IBC Technical Services Ltd., 1989: 45-56.
14. Rodger IW. Calcium channels in airway smooth muscle. Amer Rev Resp Dis 1987; 136: S15-6.
15. Barnes PJ. Asthma therapy in the future. In: Barnes PJ (Ed.). Respiratory Medicine: Recent Advances. Oxford: Butterworth-Heinemann Ltd., 1993: 72-87.
16. Berridge MJ. Inositol triphosphate and diacylglycerol as second messengers. Biochem J 1984; 220: 345-60.
17. Hoffman BB. Adrenoceptor-activating and other sympathomimetic drugs. In: Katzung BG, (Ed.). Basic and Clinical Pharmacology, 6th. ed. Connecticut: Appleton and Lange, 1995; 115-31.
18. Berridge MJ, Irvine RF. Inositol triphosphate, a novel second messenger in cellular signal transduction. Nature 1984; 312: 315-21.
19. + channels. Nature 1987; 330: 653-5.
20. Grandordy BM, Barnes PJ. Airway smooth muscle and disease workshops: phosphoinositide turnover. Amer Rev Resp Dis 1987; 136: S17-20.
21. Hashimoto T, Hirata M, Ito Y. A role for inositol 1,4,5-triphosphate in the initiation of agonist-induced contractions of dog tracheal smooth muscle. Br J Pharmacol 1985; 86: 191-9.
22. Garland LG. Is there a biochemical lesion in inrinsic asthma? In: Schmitz-Schumann M, Menz G, Costabel U, Page CP (Eds.). Intrinsic Asthma, Agents and Actions Supplements, Vol 28. Basel: Birkhauseer Verlag, 1989; 135-45.
23. +. Biochem J 1986; 240: 917-20.
24. Chilvers ER, Challiss RA, Willcocks AL, Potter BU, Barnes PJ, Nahorski SR. Characterisation of stereospecific binding sites for inositol 1,4,5-triphosphate in airway smooth muscle. Br J Pharmacol 1990; 99: 297-302.
25. Rasmussen H, Barrett PQ. Calcium messenger system: an integrated view. Physiol Rev 1984; 64: 938-84.
26. Nishizuka Y. The role of protein kinase C in cell surface signal transduction and tumour promotion. Nature 1984; 308: 693-8.
27. Kotlikoff MI, Murray RK, Reynolds EE. Histamine-induced calcium release and phorbol antagonism in cultured airway smooth muscle cells. Am J Physiol 1987; 253: C561-6.
28. Yoshimasa T, Sibley DR, Bouvier M, Lefkowitz RJ, Caron MG. Cross-talk between cellular signalling pathways suggested by phorbol-ester-induced adenylate cyclase phosphorylation. Nature 1987; 327: 67-70.
29. Rang HP, Dale MM. How drugs act: molecular aspects. In: Pharmacology, 2nd ed. London: Churchill Livingstone Inc., 1993: 24-48.
30. 2+-dependent protein kinase. Biochem Biophys Res Commun 1986; 135: 397-402.
31. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implications for cellular regulation. Nature 1988; 334: 661-5.
32. Guyton AC. Contraction and Excitation of Smooth Muscle. Textbook of Medical Physiology, 8th ed. Philadelphia: W.B. Saunders Company, 1991: 87-95.
33. Ellis JL, Undem BJ. Pharmacology of non-adrenergic, non-choloinergic nerves in airway smooth muscle. Pulm Pharmacol 1994; 7: 205-23.
34. Ramnarine SI, Rogers DF. Non-adrenergic, non-cholinergic neural control of mucus secretion in the airways. Pulm Pharmacol 1994; 7: 19-33.
35. Widdicombe JG. The neuronal component of asthma. In: Schmitz-Schumann M, Menz G, Costabel U, Page CP (Eds.). Intrinsic Asthma, Agents and Actions Supplements, Vol 28. Basel: Birkhauser Verlag, 1989; 213-24.
36. Smart SJ, Casale TB. Pathogenesis of asthma. In: Gershwin ME, Halpern GM (Eds.). Bronchial Asthma, Principles of Diagnosis and Treatment, 3rd ed. New Jersey: Humana Press, 1994: 23-55.
37. Tattersfield AE. Prospects for bronchodilating drugs in the 1990s. In: Anderson GP, Chapman ID, Morley J (Eds.). New Drugs for Asthma Therapy, Agents and Actions Supplements, Vol 34. Basel: Birkhauser Verlag, 1990: 157-76.
38. Jones CA, Madison JM, Tom-Moy M, Brown JK. Muscarinic cholinergic inhibition of adenylate cyclase in airway smooth muscle. Am J. Physiol 1987; 253: C97-104.
39. Bonner TI, Buckley NJ, Young AC, Brann MR. Identification of a family of muscarinic acetylcholine receptor genes. Science 1987; 237: 527-32.
40. Hammer R, Berrie CP, Birdsall NJ, Burgen AS, Hulme EC. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 1980; 283: 90-2.
41. Barnes PJ. Muscarinic receptor subtypes in airways (Editorial). Eur Respir J 1993; 6: 328-31.
42. Faulkner D, Fryer AD, Maclagan J. Postganglionic muscarinic inhibitory receptors in pulmonary parasympathetic nerves in the guinea-pig. Br J Pharmacol 1986; 88: 181-7.
43. Barnes PJ. New developments in anticholinergics and cholinergic pharmacology. In: Barnes PJ (Ed.). Drugs for Asthma. London: IBC Technical Services Ltd., 1989: 33-44.
44. Kurtenbach E, Curtis CA, Pedder EK, Aiken A, Harris AC, Hulme EC. Muscarinic acetylcholine receptors. Peptide sequencing identifies residues involved in antagonist binding and disulfide bond formation. J Biol Chem 1990; 265: 13702-8.
45. Barnes PJ. Muscarinic receptor subtypes: implications for therapy. In: Hansel TT, Morley J (Eds.). New Drugs for Allergy and Asthma, Agents and Actions Supplements, Vol 43. Basel: Birkhauser Verlag, 1993: 243-52.
46. Schlueter DP. Ipratropium bromide in asthma. A review of the literature. Am J Med 1986; 81: 55-60.
47. Cugell DW. Clinical pharmacology and toxicology of ipratropium bromide. Am J Med. 1986; 81: 18-22.
48. Gross NJ. Ipratropium Bromide. N Engl J Med 1988; 319: 486-94.
49. Connolly CK. Adverse reaction to ipratropium bromide BMJ 1982; 285: 934-5.
50. Gal TJ. Bronchial hyperresponsiveness and anaesthesia: physiological and therapeutic perspectives. Anaesth Analg 1994; 78: 559-73.
51. Rebuck AS, Chapman KR, Abboud R. et al. Nebulised anticholinergic and sympathomimetic treatment of asthma and chronic obstructive airways disease in the emergency room. Am J Med 1987; 82: 59-64.
52. Lefkowitz RJ, Hoffman BB, Taylor P. Neurohumoral transmission: the autonomic and somatic motor nervous system. In: Gilman AG, Rall TW, Nies AS, Taylor P (Eds.). Goodman's and Gilman's The Pharmacological Basis of Therapeutics, 8th ed. USA: Pergamon Press, 1990, 84-121.
53. Church MK, Hiroi J. Inhibition of IgE-dependent histamine release from human dispersed lung mast cells by anti-allergic drugs and salbutamol. Br J Pharmacol 1987; 90: 421-9.
54. Paterson JW, Lulich KM, Goldie RG. An overview of the current staus of the drug therapy of asthma. In: O'Donell SR, Persson CGA (Eds.). Directions for New Anti-asthma Drugs, Agents and Actions Supplements, Vol 23. Berlin: Birkhauser Verlag, 1988; 15-33.
55. Anderson GP. Pharmacology of formoterol: an innovative bronchodilator. In: Anderson GP, Chapman ID, Morley J (Eds.). New Drugs for Asthma Therapy, Agents and Actions Supplements, Vol 34. Basel: Birkhauser Verlag, 1990: 97-115.
56. Barnes PJ. Beta-adrenoceptors on smooth muscle, nerves and inflammatory cells. Life Sci 1993; 52: 2101-9.
57. Warrell DA, Robertson DG, Howes JN, et al. Comparison of cardiorespiratory effects of isoprenaline and salbutamol in patients with bronchial asthma. BMJ 1970; 1: 65-70.
58. Bloomfield P, Carmachael J, Petrie GR, Jewell NP, Crompton GK. Comparison of salbutamol given intravenously and by intermittent positive pressure breathing in life threatening asthma. BMJ 1979; 1: 848-50.
59. 2-adrenoceptor agonist bronchodilator. Life Sci 1993; 52: 2145-60.
60. Johnson M, Butchers PR, Coleman RA, et al. The pharmacology of salmeterol. Life Sci 1993; 52: 2131-43.
61. Johnson M. Salmeterol: a novel drug for the treatment of asthma. In: Anderson GP, Chapman ID, Morley J (Eds.). New Drugs for Asthma Therapy, Agents and Actions Supplements, Vol 34. Basel: Birkhauser Verlag, 1990; 79-95.
62. Anderson GP. Long acting inhaled beta-adrenoceptor agonists the comparitive pharmacology of formoterol and salmeterol. In: Hansley TT, Morley J (Eds.). New Drugs in Allergy and Asthma. Basel: Birkhauser Verlag, 1993: 252-69.
63. 2-adrenoceptor agonists: a new perspective in the treatment of asthma. Eur Respir J 1991; 4: 218-26.
64. International Report on Asthma. International Concensus Report on Diagnosis and Treatment of Asthma. Eur Respir J 1992; 5: 601-41.
65. Svensson L-Ä. Bambuterol, a bronchodilator prodrug with sustained action. In: O'Donnell SR, Persson CGA (Eds.). Directions for New Anti-asthma Drugs, Agents and Actions Supplements, Vol 23. Basel: Birkhauser Verlag, 1987: 271-6.
66. Palmer JBD. β-Agonists in asthma-current status and future developments. In: Barnes PJ (Ed.). New Drugs for Asthma. London: IBC Technical Services Ltd., 1989: 12-20.
67. Palma-Carlos AG. Basic aspects of therapy in intrinsic asthma. In: Schmitz-Schumann M, Menz G, Costabel U, Page CP (Eds.). Intrinsic Asthma, Agents and Actions Supplements, Vol 28. Basel: Birkhauser Verlag, 1989: 263-77.
68. Sears MR, Taylor DR, Print C, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet 1990; 336: 1391-6.
69. Pauwels R. The pharmacological treatment of asthma in adults. In: Gershwin ME, Halpern GM (Eds.). Bronchial Asthma, 3rd ed. New Jersey: Humana Press, 299-303.
70. Barnes PJ. Overview of current therapy. In: Barnes PJ (Ed.). New Drugs for Asthma. London: IBC Technical Services Ltd. 1989: 1-11.
71. Hoffman BB and Lefkowitz RJ. Adrenergic receptor antagonists. In: Gilman AG, Rall TW, Nies AS, Taylor P (Eds.). Goodman's and Gilman's, The Pharmacological Basis of Therapeutics, 8th ed. USA: Pergamon Press, 1990: 221-43.
72. Cockcroft DW, Murdoch KY. Comparative effects of inhaled salbutamol, sodium cromoglycate and beclomethasone diproprionate on allergen-induced early asthmatic responses, late asthmatic responses, and increased bronchial responsiveness to histamine. J Allergy Clin Immunol 1987; 79: 734-40.
73. Vathenen AS, Knox AJ, Higgins BG, Britton JR, Tattersfield AE. Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline. Lancet 1988; 1: 554-8.
74. Dompeling E, van Schayck CP, Molema J, Folgering H, van Grunsven PM, van Weel C. Inhaled beclomethasone improves the course of asthma and COPD. Eur Respir J 1992; 5: 945-52.
75. McAllen MK, Kochanowski SJ, Shaw KM. Steroid aerosols in asthma: an assessment of betamethasone valerate and a 12-month study of patients on maintenance treatment. BMJ 1974; 1: 171-5.
76. Barnes PJ. Pulmonary Disorders. In: Melmon KL, Morrelli HF, Hoffman BB, Nierenberg DW (Eds.). Melmon and Morrelli's Clinical Pharmacology, 3rd ed. USA: McGraw-Hill Inc., 1992: 186-218.
77. Andersson PT, Persson CGA. Developments in anti-asthma glucorticoids. In: O'Donnell SR, Persson CGA (Eds.). Directions for New Anti-asthma Drugs, Agents and Actions Supplements, Vol 23. Basel: Birkhauser Verlag, 1988: 239-60.
78. Persson CG. Antiinflammatory thaerapy with glucocorticoids in intrinsic asthma. In: Schmitz-Schumann M, Menz G, Costabel U, Page CP (Eds.). Intrinsic Asthma, Basel: Birkhauser Verlag, 1989: 279-91.
79. Brattsand R. Glucocorticosteroids for inhalation. In: Barnes PJ (Ed.). New Drugs for Asthma, London: IBC Technical Services Ltd., 1989: 117-30.
80. Kern JA, Lamb RJ, Reed JC, Daniele RP, Nowell PC. Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms. J Clin Invest 1988; 81: 237-44.
81. Gillis S, Crabtree GR, Smith KA. Glucocorticoid-induced inhibition of T cell growth factor production. I. The effect on mitogen-induced lymphocyte proliferation. J Immunol 1979; 123: 1624-31.
82. Raghavachar A, Fleischer S, Frickhofen N, Heimpel H, Fleischer B. T lymphocyte control of human eosinophilic granulopoiesis. Clonal analysis in an idiopathic hypereosinophilic syndrome. J Immunol 1987; 139: 3753-8.
83. Carnuccio R, DiRosa M, Guerrasio B, et al. Vasocortin: a novel glucocorticoid-induced anti-inflammatory protein. Br J Pharmacol 1987; 90: 443-5.
84. Morris HG. Mechanisms of action and therapeutic role of corticosteroids in asthma. J Allergy Clin Immunol 1985; 75: 1-13.
85. Boushey HA. Bronchodilators and other agents used in asthma. In: Katzung BG (Ed.). Basic and Clinical Pharmacology, 6th ed. Connecticut: Appleton & Lange, 1995: 305-21.
86. Persson CG. Development of safer xanthine drugs for treatment of obstructive airway disease. J Allergy Clin Immunol 1986; 78: 817-24.
87. Barnes PJ. New drugs for asthma. Eur Respir J 1992; 5: 1126-36.
88. Persson CG. Role of plasma exudation in asthmatic airways. Lancet 1986; 2: 1126-9.
89. Barlinski J, Lockhart A, Frossard N. Modulation by theophylline and enprophylline of the excitatory non-cholinergic transmission in guinea-pig bronchii. Eur Respir J 1992; 5: 1201-5.
90. Stirt JA, Sullivan SF. Aminophylline. Anesth Analg 1981; 60: 587-602.
91. Tobias JD, Kubos KL, Hirshman CA. Aminophylline does not attenuate histamine-induced airway constriction during halothane anaesthesia. Anesthesiology 1989; 71: 723-9.
92. + channel activation. Pulm Pharmacol 1994; 7; 195-203.
93. McCann JD, Welsh MJ. Calcium-activated potassium channels in canine airway smooth muscle. J Physiol (Lond) 1986; 372: 113-27.
94. Arch JR, Buckle DR, Bumstead J, Clarke GD, Taylor JF, Taylor SG. Evaluation of the potassium channel activator cromakalim (BRL34915) as a bronchodilator in the guinea-pig: comparison with nifedipine. Br J Pharmacol 1988; 95: 763-70.
95. Buckle DR. Prospects for potassium channel activators in the treatment of airways obstruction. Pulm Pharmacol 1993; 6: 161-3.
96. Williams AJ, Lee TH, Cochrane GM, et al. Attenuation of nocturnal asthma by cromakalim. Lancet 1990; 336: 334-6.
97. Barnes PJ. Control of airway Caliber. In: Fishman A (Ed.). Update: Pulmonary Diseases and Disorders. New York: McGraw-Hill Inc., 1992: 53-66.
98. Williams AJ. Potassium Channel Activators. In: Barnes PJ (Ed.). New Drugs for Asthma. London: IBC Technical Services, 1989: 57-65.
99. McCormack DG, Crawley DE, Evans TW. New perspectives in the pulmonary circulation and hypoxic pulmonary vasoconstriction. Pulm Pharmacol 1993; 6: 97-108.
100. Persson CG. Role of plasma exudation into asthmatic airways. Lancet 1986; 2: 1126-9.
101. Kroegel C. Does airway smooth muscle care about platelet-activating factor? (Editorial). Eur Respir J 1192; 5: 915-8
102. Shindo K, Matsumoto Y, Sumitomo M, Matsumura M, Okubo T. Measurement of leukotriene C4 and D4 inarterial blood of asthmatic patients during remission. Ann Allergy 1991; 66: 405-10.
103. Barnes NC, Piper PJ, Costello JF. Comparitive effects of inhaled leukotrienes C4, leukotriene D4, and histamine in normal hyman subjects. Thorax 1984; 39: 500-4.
104. Persson CG, Draco AB. Xanthines as airway antiinflammatory drugs (Letter). J Allergy Clin Immunol 1988; 81: 615-7.